TRIALS STATUS

Active/Enrolling
June 19, 2019

INTERCEPT PHARMACEUTICALS, INC. (747-304)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of…
Read More